Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.

ABSTRACT:

Objective

To evaluate the feasibility of using a multigene signature to tailor individualised adjuvant therapy for patients with operable triple negative breast cancer.

Design

Randomised, multicentre, open label, phase 3 trial.

Setting

7 cancer centres in China between 3 January 2016 and 17 July 2023.

Participants

Female patients aged 18-70 years with early triple negative breast cancer after definitive surgery.

Interventions

After risk stratification using the integrated signature, patients at high risk were randomised (1:1) to receive an intensive adjuvant treatment comprising four cycles of docetaxel, epirubicin, and cyclophosphamide followed by four cycles of gemcitabine and cisplatin (arm A; n=166) or a standard treatment of four cycles of epirubici

SUBMITTER: He M 

PROVIDER: S-EPMC11497771 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature